Rachel King has spent nearly all her career in the biotechnology industry, with stints at small companies, big pharma, and venture capital. She is currently CEO of GlycoMimetics, a publicly traded company, which she cofounded. GlycoMimetics is a clinical-stage biotechnology company that uses a specialized carbohydrate-based chemistry platform to discover and develop novel drugs to address unmet medical needs. The company’s most advanced drug candidate, uproleselan, is in clinical trials treating patients with acute myeloid leukemia, or AML.
